Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Our sample is representative of
2023-05-17

Our sample is representative of mRCC treated with sunitinib. However, the results from CCC setting have limited inference due to small exploratory sample (n = 51). Additionally, the significance of survival differences in CCC according to AXL staining is tangential. Unfortunately, we were unable to
-
br Materials and methods br Results and discussion br
2023-05-17

Materials and methods Results and discussion Conclusion Funding This work was supported by the Canadian Institute of Health Research (CIHR) [grant number FDN-148413] to PS, the National Science and Engineering Research Council of Canada (NSERC) [grant number CRD-399680] to ÉM, and the FR
-
br Conclusion br Acknowledgments and disclosure We thank
2023-05-17

Conclusion Acknowledgments and disclosure We thank Ms. Crystal Wylie for her help in the preparation of the manuscript. The development of the database upon which analyses of this study were dependent was supported by PO1 DC 00161 from the National Institute on Deafness and Other Communication
-
In the present study a splice acceptor site mutation c
2023-05-17

In the present study, a splice acceptor site mutation (c.1769-1G > C) was identified in AR gene from patients with CAIS. The c.1769-1G > C mutation results in replacement of the normal sequence (CAG/G) with a new sequence (CAC/G) at the splice acceptor site of intron 2. In the splice acceptor site r
-
n acetylneuraminic acid mg Electron paramagnetic resonance s
2023-05-17

Electron paramagnetic resonance studies of mixtures of Aβ1–40 and Aβ1–42 suggest that interlaced fibrils might also form [40] where Aβ1–40 and Aβ1–42 is found within the same fibril. Considering the Aβ fold rather than the sequence, these observations imply two mechanisms that might lower the total
-
br Available treatment modalities for
2023-05-17

Available treatment modalities for individuals with NAFLD There are several treatment modalities currently used or in clinical trials for individuals with NAFLD. The most widely recommended treatment is a lifestyle modification plan. As little as 5% weight loss has been shown to improve NASH hist
-
In this study PRP positively regulated MIIP levels and
2023-05-15

In this study, PRP4 positively regulated MIIP levels and significantly inhibited the invasion of HCT116 cells. Further investigations elucidated that PRP4 dephosphorylated MIIP via PP1A regulation, which was confirmed by PP1A inhibition in the presence of OA. Upon dephosphorylation, MIIP possibly in
-
Introduction br This paper is a commentary
2023-05-15

Introduction This paper is a commentary on the history of language among the Aché. What was language for the Aché prior to contact with Paraguayan society? How has the Aché language come to be endangered? Why is language such an important issue today? In exploring these questions I come to a slig
-
Interestingly a homolog of C elegans acr is
2023-05-15

Interestingly, a homolog of C. elegans acr-23 is present in the A. suum gamma secretase inhibitor (Jex et al., 2011). However, A. suum is not susceptible to monepantel treatment in vivo (Tritten et al., 2011). Our research seeks to advance knowledge on the mode of action of monepantel on nAChRs from
-
An alternative to the agonist or antagonist potential
2023-05-15

An alternative to the agonist or antagonist potential in drug discovery is the positive allosteric modulator (PAM) approach, which can augment the normal processes of neurotransmission as opposed to directly replacing or antagonizing them. PAMs are thought to bind to sites that are distinct from the
-
br Experimental procedure br Funding The present study was s
2023-05-15

Experimental procedure Funding The present study was supported by the Grant Russian Foundation for basic research (project no. 16-04-01517). Introduction 5-HT, a monoaminergic neurotransmitter, is synthesised from l-tryptophan catalysed by the enzymes tryptophan hydroxylase (Tph) and aroma
-
br Materials and methods br Results br Discussion
2023-05-15

Materials and methods Results Discussion We have developed a high-throughput functional genomic screen that allows the identification of genes that confer drug resistance. Several factors have been identified which must be taken into account to develop a reliable screen. In particular, cons
-
ATM dependent initiation of radiation induced
2023-05-15

ATM-dependent initiation of radiation-induced G2/M checkpoint arrest is well established [11], [34], [35]. However, the ATR pathway may also be involved [36], [37]. Brown and Baltimore generated Cre/lox-conditional cell lines or Carmoxirole hydrochloride mg with a kinase inactive allele of ATR (ATR
-
It has also been reported that defects
2023-05-15

It has also been reported that defects in ATM or ATR signalling are synthetically lethal with PARP inhibition (Turner et al., 2008, Peasland et al., 2011, Yap et al., 2011, Michels et al., 2014), suggesting that combined inhibition of PARP and ATM or ATR may be an effective therapeutic strategy. In
-
The excellent safety profile of solanezumab and encouraging
2023-05-15

The excellent safety profile of solanezumab and encouraging trends in the exploratory analyses in mild AD led to its inclusion in two secondary prevention trials, which are continuing in the hope that earlier intervention may yield more substantial benefit. The A4 study (NCT02008357) started in Febr
16373 records 335/1092 page Previous Next First page 上5页 331332333334335 下5页 Last page